Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value

Fineline Cube Mar 10, 2026
Company Deals Drug

Novo Nordisk Settles with Hims & Hers – Ozempic Wegovy Distribution Deal Ends Patent Litigation, Eliminates Compounded GLP-1 Advertising

Fineline Cube Mar 10, 2026
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026
Company Deals

Boan Biotech Partners with DP Technology on AI4S Drug Discovery – Antibody, ADC, and TCE Pipeline Acceleration

Fineline Cube Mar 6, 2026
Company Deals

AstraGenomics and Kactus Forge Gene Editing Partnership – Global Commercial Rights and Manufacturing Scale-Up for Nucleic Acid Therapeutics

Fineline Cube Mar 5, 2026
Policy / Regulatory

FDA Streamlines Biosimilar Development – New Guidance Cuts PK Study Costs by 50%, Accelerates Path to Market

Fineline Cube Mar 10, 2026
Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Fineline Cube Mar 10, 2026
Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Fineline Cube Mar 10, 2026
Company

TheDerma’s Series A+ Round to Fund R&D and Commercialization of AhR Targeted Drugs

Fineline Cube Oct 26, 2024

TheDerma, a Shanghai-based pharmaceutical company, has announced the completion of a nearly CNY 100 million...

Policy / Regulatory

Jiangxi Province to Implement Direct Medical Insurance Fund Payments for NRDL Drugs from December 2024

Fineline Cube Oct 25, 2024

The Jiangxi Province Healthcare Security Administration and the Jiangxi Provincial Department of Finance have jointly...

Company Drug

BMS Launches Cardiac Myosin Inhibitor Camzyos in China for Obstructive Hypertrophic Cardiomyopathy

Fineline Cube Oct 25, 2024

Bristol-Myers Squibb (BMS; NYSE: BMY) has announced the official market launch of its cardiac myosin...

Company

Boston Scientific Reports 19.5% YOY Increase in Q3 Net Sales, Driven by New Product Launches and Market Expansion

Fineline Cube Oct 25, 2024

Boston Scientific Corporation (NYSE: BSX), a leading medical device manufacturer in the U.S., has announced...

Company

Hengrui Pharmaceuticals Considers HKEX Secondary Listing Amid Financing Challenges in Mainland China

Fineline Cube Oct 25, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, is reportedly planning...

Company Drug

Everest Medicines’ Velsipity Approved for Use in Select Hospitals in China’s Greater Bay Area

Fineline Cube Oct 25, 2024

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

Daiichi Sankyo’s Pexidartinib Poised for Priority Review in China for TGCT Treatment

Fineline Cube Oct 25, 2024

The official website of the Center for Drug Evaluation (CDE) under China’s National Medical Products...

Company Deals

AbbVie and Gedeon Richter Expand Partnership to Develop Novel Neuropsychiatric Targets

Fineline Cube Oct 25, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the U.S., has announced a licensing...

Company Drug

Asieris Pharmaceuticals Gets FDA Green Light for USP1 Inhibitor APL-2302 in Advanced Solid Tumors

Fineline Cube Oct 25, 2024

Asieris Pharmaceuticals (SHA: 688176), a China-based specialist in urogenital cancer treatments, has announced that it...

Company Drug

Henlius Biotech Commences Global Phase III Trial for Serplulimab in First-Line Metastatic Colorectal Cancer

Fineline Cube Oct 25, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Drug

ImmuneOnco Biopharmaceuticals Initiates Phase Ib Study for Dual-Target Therapy in Systemic Lupus Erythematosus

Fineline Cube Oct 25, 2024

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541), a Chinese biopharmaceutical company, has announced the first...

Policy / Regulatory

China’s NHSA Sets October Dates for National Reimbursement Drug List Negotiations and Price Bidding

Fineline Cube Oct 25, 2024

The National Healthcare Security Administration (NHSA) has announced that the one-site negotiation and price bidding...

Company Drug

Sanofi’s Dupixent Demonstrates Positive Results in Phase III Study for Chronic Urticaria

Fineline Cube Oct 25, 2024

Sanofi (NASDAQ: SNY), the French pharmaceutical giant, has announced the presentation of new data from...

Company Deals

3SBio Secures Exclusive Rights to Commercialize Haihe’s Paclitaxel Oral Solution in China and Hong Kong

Fineline Cube Oct 25, 2024

Shanghai Haihe Pharmaceutical Co., Ltd and 3SBio Inc. (HKG: 1530), two Chinese pharmaceutical companies, have...

Policy / Regulatory

China’s NMPA and Denmark’s Medicines Agency Commit to Enhanced Regulatory Cooperation

Fineline Cube Oct 25, 2024

The National Medical Products Administration (NMPA) of China and the Danish Medicines Agency have signed...

Company Deals

NucMito and Amoytop Biotech Seal Deal for Development and Commercialization of NASH Drug Candidate in Greater China

Fineline Cube Oct 25, 2024

NucMito, a pioneering nuclear receptor drug developer headquartered in Xiamen, has entered into a licensing...

Company Deals

HELP Therapeutics Receives FDA Clearance for Phase I Clinical Trial of HiCM-188 Cell Therapy

Fineline Cube Oct 25, 2024

HELP Therapeutics Co. Ltd, a clinical-stage cell therapy company headquartered in Nanjing, has announced that...

Company Deals

Merck Acquires Modifi Biosciences to Target DNA Repair Defects in Cancer Therapies

Fineline Cube Oct 24, 2024

Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK), a leading U.S. pharmaceutical company, has bolstered...

Company Drug

Eli Lilly’s Alzheimer’s Drug Kisunla Secures Marketing Approval in Great Britain

Fineline Cube Oct 24, 2024

Eli Lilly & Co. (NYSE: LLY) has announced that it has received marketing approval in...

Company Medical Device

Sino Medical Sciences Technology Secures Marketing Approval for Coronary Balloon Dilation Catheter in Morocco

Fineline Cube Oct 24, 2024

Sino Medical Sciences Technology Inc., (SHA: 688108) a China-based medical device company, has announced that...

Posts pagination

1 … 245 246 247 … 632

Recent updates

  • SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure
  • Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential
  • Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors
  • Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market
  • GSK Licenses Linerixibat to Alfasigma for $300 Million Upfront – IBAT Inhibitor Targets PBC Pruritus with $690 Million Total Deal Value
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

SicaGene’s SG12 ASO Wins NMPA Approval – Antisense Oligonucleotide Targets Hepatitis B Functional Cure

Company Drug

Kelun-Biotech’s SKB575/HBM7575 Wins NMPA Approval – Long-Acting TSLP Bispecific Targets Atopic Dermatitis with Q3+ Dosing Potential

Company Drug

Henlius Biotech’s HLX3901 Wins NMPA Approval – First-in-Class Tetra-Specific Antibody Targets DLL3-Positive Solid Tumors

Company Drug

Qyuns Therapeutics’ QX002N NDA Accepted by NMPA – IL-17A Antibody Targets Ankylosing Spondylitis Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.